A Potential Administration-time Dependent Effect of Bevacizumab in Improving Overall Survival and Increasing Metastasis in Metastatic Colorectal CancerBei Zhang1,2#, Wenzhuo He1,2#, Feifei Zhou3, Guifang Guo1,2, Chang Jiang1,2, Chenxi Yin1,2, Xuxian Chen1,2, Huijuan Qiu1,2, Yuming Rong1,2 and Liangping Xia1,2*
- *Corresponding Author:
- Liangping Xia
State Key Laboratory of Oncology in South China
Sun Yat-sen University Cancer Center, Guangzhou, P.R. China
E-mail: [email protected]
Received date: June 14, 2013; Accepted date: July 15, 2013; Published date: July 19, 2013
Citation: Zhang B, He W, Zhou F, Guo G, Jiang C, et al. (2013) A Potential Administration-time Dependent Effect of Bevacizumab in Improving Overall Survival and Increasing Metastasis in Metastatic Colorectal Cancer. Chemotherapy 2:108. doi: 10.4172/2167-7700.1000108
Copyright: © 2013 Zhang B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: The effectiveness of Bevacizumab has been demonstrated for the treatment of metastatic colorectal cancer. However, the minimum number of bevacizumab cycles needed to improve overall survival is unknown. In addition, anti-angiogenic treatment has been shown in preclinical studies to accelerate metastasis. To investigate these two issues, we performed a retrospective case-control study in Chinese patients with metastatic colorectal cancer.
Methods: Patients initially diagnosed as metastatic colorectal cancer at the Sun Yat-sen University Cancer Center from 2004 to 2010 were recruited. All patients treated with bevacizumab served as experimental group; patients not treated with bevacizumab were control group. The primary endpoints were overall survival and the incidence of new metastatic lesions in the liver and other organs.
Results: Patients received more than 4 cycles of bevacizumab showed a significantly prolonged overall survival than patients in the control group. The median overall survival was 31.53 months (95% CI, 23.22-39.85 months) and 19.70 months (95% CI, 16.61-22.79 months; P=0.031) for the experimental and control groups, respectively. The patients receiving bevacizumab more than 3 times showed an increased risk compared to the patients in control group of developing new metastatic lesions in the liver (17/23 versus 25/55, respectively, P=0.022) and other organs (14/23 versus 19/55, respectively, P=0.032).
Conclusion: More than 4 doses of bevacizumab were required to improve overall survival in metastatic colorectal cancer; a potentially accelerated metastasis rate was observed after more than 3 doses of bevacizumab. However, studies with larger patient sample sizes are urgently needed to validate our findings.